hazard ratio (HR) including 95% CI is plotted in dependence of the cutoff. A vertical line designates the dichotomization showing the most significant correlation with survival. The distribution of the neutrophil count in the 265 patients is shown as a rug plot at the bottom of the figures.
Supp. Figure 3: Subgroup analysis of survival in function of bevacizumab usage at
recurrence and neutrophil count using neutrophil count determine at recurrence A. Kaplan-Meier estimates of overall survival in patients treated or not with bevacizumab in the subgroup of patients with a high (≥6000/mm3) neutrophil count at recurrence. B. Kaplan-Meier estimates of overall survival in patients treated or not with bevacizumab in the subgroup of patients with a low (<6000/mm3) neutrophil count at recurrence. C. Kaplan-Meier estimates of overall survival in patients with a high (>6000/mm3) versus low neutrophil count at recurrence in the subgroup of patients treated with chemotherapy with bevacizumab in the training cohort. D. Kaplan-Meier estimates of overall survival in patients with a high (>6000/mm3) versus low neutrophil count at recurrence in the subgroup of patients treated with chemotherapy without bevacizumab
Supp. Figure 4: Partial least square regression model using CSF3 expression to predict the type of angiogenic process
Patients were divided into two groups based on the CSF3 expression median (lower or higher than median). A PLS model was estimated with these 2 groups of CSF3 expression levels as response factor. A 10-fold cross-validation procedure was then used to validate the predictive power of the model and led to 75% of correct classifications Supplementary Table 4. 
